Business brief
Strategic Pivots and Balance Sheet Tests
From Teva’s biosimilar expansion to Enlight’s AI grid demand, Israeli corporate leaders execute aggressive margin pivots.
Business
Teva bought immediate access to the lucrative US immunology market — locking down high-margin biologic distribution while Samsung Bioepis absorbs manufacturing risk.
BackgroundBiosimilars are near-identical, lower-cost copies of complex biologic therapies that treat chronic inflammatory disorders like rheumatoid arthritis and colitis. Teva has spent years shedding low-margin commodity generics to rebuild cash flows around higher-margin complex specialty drugs.
- Teva gains immediate exclusive US distribution rights to ETICOVO for arthritis, while commercial rights to infliximab-abda transfer to the Tel Aviv-based drugmaker in Q3 2027.
- Samsung Bioepis retains clinical oversight and contract manufacturing responsibilities, allowing Teva to plug both immunology therapies directly into its North American hospital and clinic sales force.
- Chief Executive Richard Francis noted the deal diversifies core US revenue, arriving alongside third-quarter free cash flow of $495 million that supports continued debt reduction.
Business
Tower converted optical AI server bottlenecks into a $2B foundry business — insulating its specialty fabs from broader consumer electronics chip slumps.
BackgroundHigh-density AI server clusters suffer significant speed bottlenecks and heat waste when routing data through conventional copper cabling. Silicon photonics solves this by using laser light pulses directly on semiconductor chips, drastically expanding data transmission bandwidth while lowering power draw.
- Tower's operating profit surged 2.5-fold to $127 million while net margin reached 23%, buoyed by high-margin optical foundry wafer orders.
- Chief Executive Russell Ellwanger confirmed that silicon photonics manufacturing capacity will account for more than $1.1 billion of the company’s annual revenue base.
- Despite the record operational forecast, dual-listed shares slipped in Tel Aviv trading as global semiconductor multiple compression weighed on specialty foundry valuations.
Business
Enlight is monetizing Israel’s severe energy bottlenecks — converting domestic AI server expansion into locked-in, long-term corporate clean power purchase contracts.
BackgroundIsrael faces severe grid constraints as expanding military infrastructure, desalination plants, and tech data centers compete for baseload power. Enlight develops and finances utility-scale solar, wind, and battery storage projects across Israel, Europe, and the United States.
- Israeli electricity trading revenue surged 100% year-over-year to $56 million in Q3, pushing nine-month domestic power sales to $114 million.
- Management boosted full-year 2026 revenue guidance to $810M–$830 million, well above its previous midpoint projection of $770 million.
- Net income jumped 76% to $34 million as long-term corporate power purchase agreements insulated cash flow from merchant spot price swings.
Business
Arkia’s $30M operating shortfall forced a bitter ownership showdown — pitting billionaire controlling owners against workers fighting dilution of their statutory equity stake.
BackgroundArkia is Israel’s second-largest carrier, providing essential domestic shuttle services between Tel Aviv and the southern resort port of Eilat alongside Mediterranean charters. Company staff own a statutory 20% equity stake secured through collective bargaining agreements negotiated during previous state privatization rounds.
- The Transport and Seaports Workers' Union launched a labor dispute, warning that unilateral equity dilution violates historic collective bargaining pacts.
- The carrier initiated operational cutbacks including luggage fee hikes and regional codeshare deals to stem ongoing cash burn before winter travel slows.
- Prolonged labor disruptions would sever domestic air connectivity to Eilat at a time when major foreign airlines continue to cancel flights into Ben Gurion Airport.
Business
Business
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
